Autism Spectrum Disorder

Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1.  PharmAla-1 was discovered through computational in-silico modeling exercises via an innovation grant-funded partnership with University...

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started recruiting participants for the first-ever clinical trial assessing the effects of psilocybin in adults diagnosed with Fragile X Syndrome (FXS), the leading genetic...

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder. KGK and its client Nova Mentis (OTC: NMLSF) are set to conduct this pioneering...

SciSparc Ltd. (NASDAQ: SPRC), a pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced it has signed an agreement with the Soroka University Medical Center, located in Be'er-Sheva, Israel. What's It About? SciSparc,...